Individualized ocular characteristics should be considered before starting GLP-1 RA therapies for weight loss and diabetes management.

Patients with diabetes who utilize GLP-1 RAs for 6 months or longer are twice as likely to develop neovascular age-related macular degeneration.

In patients with moderate peripheral artery disease, use of GLP-1 RAs increases the likelihood of more favorable cardiovascular and major limb outcomes.

New research links semaglutide and tirzepatide, which are GLP-1 agonists used to treat type 2 diabetes and aid weight loss, ...

GLP-1 drugs show promise in diabetes management, offering heart and kidney benefits, but also highlight the need for ...

Individuals with type 2 diabetes who receive treatment with GLP-1 RAs do not have an increased risk for acute pancreatitis.

There were associations for GLP-1 RA treatment vs placebo with improvements in restrained eating and emotional eating behavior and in mental health-related QOL. HealthDay News — For patients ...

glucagon-like peptide 1 receptor agonist (GLP-1 RA) treatment is not associated with an increased risk for psychiatric adverse events or worsening depressive symptoms, according to a study ...

Data were included for 85,015 adults with a body mass index ≥30 kg/m 2 and a diagnosis of diabetes who newly initiated a GLP-1 RA or DPP-4 inhibitor between 2013 and 2023. Patients prescribed ...

Protective associations were seen between GLP-1 RA use and colon and rectal cancers. "Our results suggest [GLP-1 RAs] may modestly cut the chance of developing certain cancers—especially cancers ...

76, with low certainty) between GLP-1 RAs and placebo. GLP-1 RA treatment was associated with significantly improved restrained eating and reduced emotional eating. This finding, said the authors ...